Zydus Lifesciences Ltd has obtained final authorisation from the US Food and Drug Administration (USFDA) for its generic variant of Eltrombopag tablets, as stated in a regulatory filing. The authorisation includes various dosage strengths, 12.5 mg, 25 mg, 50 mg, and 75 mg, allowing the company to sell and distribute the product in the United States, a major global pharmaceutical market. Eltrombopag tablets are used to treat thrombocytopenia, a condition marked by reduced platelet counts linked to specific blood disorders. The authorisation represents yet another addition to Zydus Lifesciences’ growing collection of USFDA-approved generic drugs, highlighting the firm’s ongoing emphasis on regulated markets and its dedication to creating products that satisfy rigorous global regulatory criteria. The firm announced that the authorised tablets will be produced at its formulation plant situated in the Special Economic Zone (SEZ) in Ahmedabad, bolstering its export-focused pharmaceutical activities. According to the IQVIA MAT data from November 2025 referenced in the regulatory filing, Eltrombopag tablets achieved yearly sales of Rs. 10,480 crore (US$ 1.26 billion) in the American market, highlighting the product's commercial importance. The authorisation enhances Zydus Lifesciences’ expanding range of USFDA-approved products and bolsters its position in the regulated generics market. The firm highlighted that the approval strengthens its commitment to complex and speciality generics while improving its capacity to meet demand in major international markets, especially the United States